Biology subjects

Ekström, S.

Publications and source records attributed to Ekström, S..

6 recordsLinked to original sources

bioRxiv2026

Structural profiling of the pneumolysin epitope landscape uncovers a cross-species neutralising site across cholesterol-dependent cytolysins

Streptococcus pneumoniae remains a major public health concern, largely due to the limited serotype coverage and other constraints of pneumococcal conjugate vaccines, as well as the increasing antimicrobial resistance among circulating strains. In the pursuit of protein-based pneumococcal vaccines, pneumolysin (PLY), a secreted multifunctional cholesterol-dependent cytolysin, represents a promising target. To date, the relationship between the B-cell epitope landscape and neutralising PLY-specific antibody responses has remained elusive, hindering the rational design of effective PLY-based vaccines. Using a panel of PLY-specific monoclonal antibodies, functional assays, multimodal protein mass spectrometry and data-driven computational modelling, we mapped the structural epitope landscape of native PLY and linked epitope-paratope interactions to neutralising potency. We further refined and structurally characterised a protective cross-species epitope conserved among homologous cholesterol-dependent cytolysins (CDC). This epitope provides a promising foundation for rational, epitope-focused vaccine design, offering a pathway toward species-independent vaccines targeting the CDC protein superfamily.

immunology↗

bioRxiv2025

Design of a Streptolysin O Epitope-Centric Nanoparticle Vaccine Against Streptococcus pyogenes

Streptococcus pyogenes (Group A Streptococcus, GAS) is a significant human pathogen for which no licensed vaccine is currently available. Here, we report a de novo designed epitope-centric protein-based nanoparticle vaccine against GAS. By integrating structural mass spectrometry techniques and deep learning approaches, we re-engineered a protective epitope (D3m) present in domain 3 of streptolysin O, a prominent pore-forming toxin produced by GAS. D3m was displayed on the surface of a self-assembling icosahedral nanoparticle (D3m-NP) to enhance epitope presentation and immunogenicity. Mice immunised with D3m-NP mounted haemolysis-neutralising titres and displayed a more uniform, epitope-centric antibody response than those receiving the community-standard detoxified full-length streptolysin O. Our findings highlight a promising strategy for GAS vaccine development by combining multimodal protein mass spectrometry, protein design and a versatile protein-based nanoparticle vaccine platform.

immunology↗

bioRxiv2024

Streptolysin O Accelerates the Conversion of Plasminogen to Plasmin

Streptococcus pyogenes is a human-specific bacterial pathogen that produces several proteins that exploit the plasminogen (PLG)-plasmin (PLM) fibrinolysis system to dismantle blood clots and to facilitate spread and survival within the host. In this study, we explored the interactions between streptolysin O (SLO), a key cytolytic toxin produced by S. pyogenes, and human plasma proteins using affinity-enrichment mass spectrometry. SLO binds specifically to PLG, and this interaction accelerates the conversion of PLG to PLM by tissue-type plasminogen activator (tPA). To further investigate the molecular detail of the PLG-SLO interaction, we employed hydrogen/deuterium exchange mass spectrometry combined with targeted cross-linking mass spectrometry, uncovering that SLO binding induces local conformational shifts in PLG. These changes lead to the formation of a stabilized intermediate PLG-SLO complex that becomes significantly more sensitive to proteolytic processing by tPA. Our findings reveal a conserved moonlighting pathomechanistic role for SLO extending beyond the well characterized cytolytic activity. Additionally, the work underscores the diversity of functional proteomics in identifying and clarifying new host-pathogen interactions.

molecular biology↗

bioRxiv2023

Multi-Modal Mass Spectrometry Identifies a Conserved Protective Epitope in S. pyogenes Streptolysin O

An important element of antibody-guided vaccine design is the use of neutralizing/opsonic monoclonal antibodies to define protective epitopes in their native three-dimensional conformation. Here, we demonstrate a multi-modal mass spectrometry-based strategy for in-depth characterization of antigen-antibody complexes to enable the identification of protective epitopes using the cytolytic exotoxin Streptolysin O (SLO) from Streptococcus pyogenes as a showcase. We first discovered a monoclonal antibody with an undisclosed sequence capable of neutralizing SLO-mediated cytolysis. The amino acid sequence of both the antibody light and the heavy chain was determined using mass spectrometry-based de novo sequencing, followed by chemical crosslinking mass spectrometry to generate distance constraints between the antibody fragment antigen-binding region and SLO. Subsequent integrative computational modeling revealed a discontinuous epitope located in Domain 3 of SLO that was experimentally validated by hydrogen-deuterium exchange mass spectrometry and reverse-engineering of the targeted epitope. The results show that the antibody inhibits SLO-mediated cytolysis by binding to a discontinuous epitope in Domain 3, likely preventing oligomerization and subsequent secondary structure changes critical for pore-formation. The epitope is highly conserved across >98% of the characterized S. pyogenes isolates, making it an attractive target for antibody-based therapy and vaccine design against severe streptococcal infections.

biochemistry↗

bioRxiv2021

Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies

Conventional approaches to isolate and characterize nanobodies are laborious and cumbersome. Here we combine phage display, multivariate enrichment, and novel sequence analysis techniques to annotate an entire nanobody repertoire from an immunized alpaca. We combine this approach with a streamlined screening strategy to identify numerous anti-SARS-CoV-2 nanobodies, and use neutralization assays and Hydrogen/Deuterium exchange coupled to mass spectrometry (HDX-MS) epitope mapping to characterize their potency and specificity. Epitope mapping revealed that the binding site is a key determinant of neutralization potency, rather than affinity alone. The most potent nanobodies bind to the receptor binding motif of the RBD, directly preventing interaction with the host cell receptor ACE2, and we identify two exceptionally potent members of this category (with monomeric IC50s around 13 and 16 ng/ml). Other nanobodies bind to a more conserved epitope on the side of the RBD, and are able to potently neutralize the SARS-CoV-2 founder virus (42 ng/ml), the beta variant (B.1.351/501Y.V2) (35 ng/ml), and also cross-neutralize the more distantly related SARS-CoV-1 (0.46 g/ml). The approach presented here is well suited for the screening of phage libraries to identify functional nanobodies for various biomedical and biochemical applications.

immunology↗

bioRxiv2020

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux

Specific mutations in Apolipoprotein A-I (ApoA-I) of high-density lipoprotein (HDL) are responsible for a late-onset systemic amyloidosis. Carriers do not exhibit increased cardiovascular disease risk despite reduced levels of ApoA-I/ HDL-cholesterol. To explain this paradox, we show that the HDL particle profile of L75P and L174S patients presents a higher relative abundance of the 8.4 nm vs 9.6 nm particles, and that serum from patients, as well as reconstituted 8.4 and 9.6 nm HDL particles (rHDL), possess increased capacity to catalyze cholesterol efflux from macrophages. Synchrotron radiation circular dichroism and hydrogen-deuterium exchange revealed that the variants in 8.4 nm rHDL have altered secondary structure composition and display a more flexible binding to lipids compared to their native counterpart. The reduced HDL-cholesterol levels of patients carrying ApoA-I amyloidogenic variants are thus balanced by higher proportion of small, dense HDL particles and better cholesterol efflux due to altered, region-specific protein structure dynamics.

biochemistry↗